Boehringer Ingelheim Pharmaceuticals, Inc. drugs
11 results
Cyltezo (adalimumab-adbm)
(adalimumab-adbm)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, either alone or with other therapies.
Gilotrif (afatinib)
(afatinib)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: GILOTRIF is indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations and for previously treated metastatic squamous NSCLC progressing after platinum-based chemotherapy. Its safety and efficacy in resistant EGFR mutations have not been established.
Glyxambi (empagliflozin and linagliptin)
(empagliflozin and linagliptin)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: GLYXAMBI is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It also reduces the risk of cardiovascular death in those with established cardiovascular disease. It is not suitable for type 1 diabetes or patients with certain renal conditions.
Jardiance (empagliflozin)
(Empagliflozin)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: JARDIANCE is indicated to reduce cardiovascular death and hospitalization in adults with heart failure, chronic kidney disease, and type 2 diabetes with cardiovascular disease. It also aids glycemic control as an adjunct to diet and exercise in patients aged 10 and older with type 2 diabetes.
Jentadueto (linagliptin and metformin hydrochloride)
(linagliptin and metformin hydrochloride)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: JENTADUETO is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not recommended for type 1 diabetes patients and has not been studied in those with a history of pancreatitis.
Ofev (nintedanib)
(nintedanib)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: OFEV is indicated for treating adults with idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and to slow pulmonary function decline in systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Spevigo (spesolimab-sbzo)
(spesolimab-sbzo)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and older, who weigh at least 40 kg.
Spiriva (tiotropium bromide)
(TIOTROPIUM BROMIDE)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: SPIRIVA HANDIHALER (tiotropium bromide) is indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and to reduce exacerbations in COPD patients.
Synjardy (empagliflozin and metformin hydrochloride)
(empagliflozin and metformin hydrochloride)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: SYNJARDY and SYNJARDY XR are indicated as adjuncts to diet and exercise for improving glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes mellitus. Empagliflozin reduces risks associated with cardiovascular death, heart failure, and chronic kidney disease progression in adults with type 2 diabetes.
Tradjenta (linagliptin)
(linagliptin)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: TRADJENTA is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not recommended for type 1 diabetes and has not been studied in patients with a history of pancreatitis.